Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line
Author:
Funder
National Research Centre
National Research Centre, Dokki, 12622, Cairo, Egypt
Publisher
Elsevier BV
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,General Medicine
Reference50 articles.
1. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer;Agrawal;Nanomed. Nanotechnol. Biol. Med.,2018
2. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands;Agulnik;J. Clin. Oncol.,2007
3. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer;Arteaga;Clin. Cancer Res.,2008
4. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer;Boussen;J. Clin. Oncol.,2010
5. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer;Burstein;Ann. Oncol.,2008
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Co-delivery of lapatinib and 5-fluorouracil transfersomes using transpapillary iontophoresis for breast cancer therapy;International Journal of Pharmaceutics;2024-01
2. Synthesis and Anticancer Evaluation of 4-Anilinoquinolinylchalcone Derivatives;International Journal of Molecular Sciences;2023-03-23
3. Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review);International Journal of Oncology;2023-01-04
4. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors;Bioorganic Chemistry;2022-11
5. Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status;Biomaterials Advances;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3